IP Library › Granted Patent US 11,723,864
Granted Patent B2
US 11,723,864 · App. 15/576,485 · Granted Aug 15, 2023

Antimicrobial and anti-inflammatory compositions

Inventors: Carolyn L. Cannon (College Station, TX); Parth N. Shah (College Station, TX); Justin A. Smolen (College Station, TX); Hugh D. Smyth (Westlake, TX); Ashkan K. Yazdi (Austin, TX); Matthew J. Herpin (Austin, TX)
Assignees: The Texas A&M University System; The Board of Regents of the University of Texas System
A61K9/0078A61K9/0075A61K31/19A61K45/06A61K47/12A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,723,864
App. No.
15/576,485
Granted
Aug 15, 2023
Kind
B2
Abstract

The claimed invention is directed to the use of a composition for use as an antimicrobial comprising an antimicrobial agent. In certain embodiments, the composition is used for treating or ameliorating inflammation in a subject and comprises an anti-inflammatory agent. The anti-inflammatory agent may include an NSAID, such as ibuprofen or diclofenac. The composition may further include solvents, anti-bacterial agents, anti-fungal agents, anti-parasitic agents, anti-viral agents, and buffers. The composition may include particles that have been processed via jet milling to reduce a diameter of the particles and to improve a flowability of the particles.

Claims (6)

1. A dry powder inhaler composition for treating or ameliorating inflammation and/or treating a disease in a subject in need thereof, wherein the composition consists of a micronized formulation of non-steroidal anti-inflammatory drug (NSAID) particles, wherein the NSAID particles and composition are carrier-free, wherein the NSAID particles consist of pure and excipient-free, undiluted NSAID, wherein the composition has a respirable fraction (RF) value of at least 50% and wherein the NSAID possesses anti-inflammatory and antimicrobial activities.

2. The inhaler composition of claim 1 , wherein the NSAID particles are produced by air jet-milling.

3. The inhaler composition of claim 2 , wherein the size of the NSAID particles ranges from 0.8 μm to 6 μm.

4. The inhaler composition of claim 1 , wherein the NSAID particles possess an angle of repose of less than 45°.

5. The inhaler composition of claim 1 , wherein the NSAID is ibuprofen, naproxen, diclofenac, or indomethacin.

6. The inhaler composition of claim 1 , wherein the composition is a free-flowing powder.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2018
From: CANNON, CAROLYN L.; SHAH, PARTH N.; SMOLEN, JUSTIN A.; SMYTH, HUGH D.; YAZDI, ASHKAN K.; HERPIN, MATTHEW J.
To: THE TEXAS A&M UNIVERSITY SYSTEM; THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 046935/0169 →
Continuity (2)
Provisional Application 62168561 · May 29, 2015
Related Publication 20180207093A1 · Jul 26, 2018
Cited By (1)
US 12,544,336